Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Luxiq was a prescription scalp foam containing betamethasone valerate 0.12 percent, a medium-potency topical corticosteroid. It was indicated to relieve inflammation and itching associated with corticosteroid-responsive scalp disorders, including scalp psoriasis. FDA lists the original Luxiq trade-name product as discontinued, while generic betamethasone valerate foam remains marketed.
read more about what was luxiq ...Betamethasone valerate acts through glucocorticoid receptors and suppresses inflammatory and immune responses in the skin. Topical corticosteroids also constrict small blood vessels, reducing visible inflammation and itching.
Luxiq was prescribed for inflammatory and itchy scalp disorders that respond to corticosteroids. It was used externally on the scalp and not in the eyes. The historical label did not establish safety and efficacy in pediatric patients.
The foam was applied to affected scalp areas twice daily, once in the morning and once at night. The can was inverted to dispense a small amount onto a cool surface before the foam was massaged into the scalp. Treatment stopped when control was achieved, and lack of improvement after two weeks prompted reassessment.
Prolonged or extensive use of topical corticosteroids can suppress the hypothalamic-pituitary-adrenal axis and cause adrenal insufficiency, Cushing syndrome, or high blood glucose. Other concerns include skin thinning, irritation, allergic contact dermatitis, and secondary skin infections. The pressurized foam was flammable and required avoidance of flames, smoking, and heat during and immediately after application.
Luxiq contained betamethasone valerate 0.12 percent in a topical foam.
It was used for inflammation and itching associated with corticosteroid-responsive scalp disorders.
No. FDA lists Luxiq as discontinued, while generic betamethasone valerate 0.12 percent foam remains marketed.
The historical directions called for application to affected scalp areas twice daily.
Approved Drug Products with Therapeutic Equivalence Evaluations 46th Edition. U.S. Food and Drug Administration. https://www.fda.gov/media/71474/download. Date Accessed October 13, 2026.
Betamethasone Topical. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682799.html. Date Accessed October 13, 2026.
Betamethasone Valerate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Betamethasone-valerate. Date Accessed October 13, 2026.
DailyMed - BETAMETHASONE VALERATE aerosol, foam. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=professional&setid=75d70e76-023c-4a00-954d-79a697bed80f. Date Accessed October 13, 2026.
DailyMed - LUXIQ (betamethasone valerate) aerosol, foam. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3dab9411-df12-4073-9cc1-3273e2aee7e7. Date Accessed October 13, 2026.